Floatz logo

Ny-Eso-1 Olp4

Unresectable or Metastatic Melanoma

Ludwig Institute for Cancer Researchprotein_peptidePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Unresectable or Metastatic Melanoma cohort.

Asset / SponsorPhaseRating
Nivolumab
Bristol-Myers Squibb
Phase 3B
Tucidinostat
HUYABIO International, LLC.
Phase 3B
st-1898 tablets
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 1/2CCC
Ny-Eso-1 Protein Vaccine
Ludwig Institute for Cancer Research
Phase 1CC
Montanide Isa 51
Ludwig Institute for Cancer Research
Phase 1CC
Ny-Eso-1 Olp4 Vaccine With Poly-Iclc
Ludwig Institute for Cancer Research
Phase 1CC
PACMILIMAB
CytomX Therapeutics
Phase 2C

Same molecule, other indications

Ny-Eso-1 Olp4 is also rated in:

ovarian carcinomaDormant
CC
Indicative ·
42 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
42 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →